Quantification immunohistochemical analysis of 90 HCV+ HCC patients specimens demonstrated that CNPY2 was strongly elevated in 55 cases (61.1%; score 2+), weakly expressed in 25 (27.8%: score 1+) and negative in 10 (11.1%; score 0) cases (Figure 4C). This evidence concerns the gene CNPY2 and hepatocellular carcinoma.